This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Innate Pharma. Active years: 2012-2014.
Company Filing History:
Years Active: 2012-2014
Title: Agnes Tisserant: Innovator in Cancer Treatment
Introduction
Agnes Tisserant is a prominent inventor based in Le Puy Ste Reparade, France. She has made significant contributions to the field of cancer treatment, particularly through her innovative research and development of antibodies targeting TLR3-positive cancer.
Latest Patents
Agnes Tisserant holds 2 patents related to her groundbreaking work. Her latest patents include methods of treating patients having TLR3-positive cancer. The first patent focuses on antibodies, antibody fragments, and derivatives that specifically bind to TLR3 cell receptors present on the surface of cells. This invention also encompasses hybridomas producing such antibodies, methods of making these antibodies, and pharmaceutical compositions comprising them. Additionally, it details methods for using the antibodies to detect TLR3 levels on the surface of cells, along with their diagnostic and therapeutic applications. The second patent similarly relates to compositions and methods for detecting TLR3, emphasizing the same innovative approaches and applications.
Career Highlights
Agnes Tisserant is associated with Innate Pharma, where she continues to advance her research in cancer therapies. Her work has been instrumental in developing new methods for diagnosing and treating cancer, showcasing her commitment to improving patient outcomes.
Collaborations
Agnes collaborates with notable colleagues, including Karine Chemin and Laurent Gauthier, who contribute to her research efforts and innovations in the field.
Conclusion
Agnes Tisserant's contributions to cancer treatment through her patents and research exemplify her dedication to innovation in medicine. Her work not only enhances our understanding of TLR3-positive cancer but also paves the way for future advancements in therapeutic approaches.